AstraZeneca PLC Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Pharmaceuticals | Market Cap: ₹5.7L Cr
- Total revenue growth: AstraZeneca expects mid- to high single-digit percentage increase for the full year 2026. - Oncology: 16% revenue growth in Q1 2026; continued growth expected with strong momentum in key products like Tagrisso, Imfinzi, Calquence, HER2 portfolio, and Datroway. - Biopharmaceuticals: Stable total revenue with growth in respiratory and immunology portfolio (+7%), driven by brands like Fasenra (+11%) and Breztri (+13%). - Pipeline & launches: Significant growth anticipated from upcoming launches such as baxrostat, gamizestrant, tozorakimab, and amplifying commercial investments. - Tozorakimab: Potential to be a $3-$5 billion asset with upside toward $10 billion depending on additional indications. - Tagrisso: Mid-teens demand growth expected, with stable U.S. - AstraZeneca expects total revenue to increase by mid- to high single-digit percentage in 2026.
From AstraZeneca PLC's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹185.33
Market Cap
₹5.7L Cr
P/E Ratio
28.1
Revenue Rank
Margin Rank
How does AstraZeneca PLC rank in Pharmaceuticals?
Compare AstraZeneca PLC against every Pharmaceuticals company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 3- →Total revenue growth: AstraZeneca expects mid- to high single-digit percentage increase for the full year 2026.
- →Oncology: 16% revenue growth in Q1 2026; continued growth expected with strong momentum in key products like Tagrisso, Imfinzi, Calquence, HER2 portfolio, and Datroway.
- →Biopharmaceuticals: Stable total revenue with growth in respiratory and immunology portfolio (+7%), driven by brands like Fasenra (+11%) and Breztri (+13%).
- →Pipeline & launches: Significant growth anticipated from upcoming launches such as baxrostat, gamizestrant, tozorakimab, and amplifying commercial investments.
- →Tozorakimab: Potential to be a $3-$5 billion asset with upside toward $10 billion depending on additional indications.
- →Tagrisso: Mid-teens demand growth expected, with stable U.S. frontline leadership and no cannibalization from other launches.
- →R&D and SG&A investments are increasing to support growth and pipeline expansion through 2030 and beyond.
📈 Profitability & Margins
Rank 3- →AstraZeneca expects total revenue to increase by mid- to high single-digit percentage in 2026.
- →Core operating profit grew by 12% in Q1 2026, reflecting strong underlying performance.
- →Core EPS grew by 5% in Q1 2026; growth was impacted by a low tax rate in the prior year.
- →Full-year guidance for core EPS anticipates low double-digit percentage growth at constant exchange rates.
- →Core gross margin is expected to be stable to slightly higher versus 2025.
- →Continued investments in R&D and commercial capabilities to support ongoing and future product launches.
- →Significant pipeline progress with multiple upcoming launches (e.g., baxrostat, tozorakimab) to drive growth through 2030 and beyond.
- →Capital allocation priorities remain unchanged, with confidence in sustaining growth through 2030.
🏗️ Capital Expenditure Plans
Yes- →CapEx for Q1 2026 was $600 million, including previously announced multiyear investments.
- →Key investments include a new ADC (antibody-drug conjugate) manufacturing facility in Singapore.
- →Construction of a new manufacturing plant in Qingdao, China, focused on inhaled respiratory portfolio.
- →CapEx is anticipated to increase by around one-third in 2026.
- →Strategic investments continue in transformative technologies such as cell therapies and T-cell engagers to drive growth beyond 2030.
- →Milestone payments of around $2.5 billion are expected for the full year, related to past transactions.
- →Recent deal: CSPC agreement closed in April, booked in Q2.
- →Investments support pipeline acceleration, including new launches like baxrostat and tozorakimab, ensuring future growth.
💰 Fundraising & Capital Structure
No information- →There is no explicit mention of planned new fundraising through debt or equity in the provided transcript.
- →Net debt increased by around $2.5 billion in the quarter, primarily due to the payment of the second FY 2025 interim dividend in March.
- →The company states it is comfortable with the current level of gross debt.
- →Milestone payments totaling around $2.5 billion are anticipated for the full year related to past transactions.
- →No announcements or indications of new equity issuance or debt fundraising strategies were disclosed in the available information.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Pharmaceuticals this season
- Elanco Animal Health Incorporated (Q2 FY26)
Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S
- Axsome Therapeutics, Inc. (Q2 FY26)
Axsome Therapeutics, Inc. Q2 FY26 quarterly results analysis. AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from
- Jazz Pharmaceuticals plc (Q2 FY26)
Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo
- Viatris Inc. (Q2 FY26)
Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7
Frequently Asked Questions
What were AstraZeneca PLC Q2 FY26 results?
- Total revenue growth: AstraZeneca expects mid- to high single-digit percentage increase for the full year 2026. - Oncology: 16% revenue growth in Q1 2026; continued growth expected with strong momentum in key products like Tagrisso, Imfinzi, Calquence, HER2 portfolio, and Datroway. - Biopharmaceuticals: Stable total revenue with growth in respiratory and immunology portfolio (+7%), driven by brands like Fasenra (+11%) and Breztri (+13%). - Pipeline & launches: Significant growth anticipated from upcoming launches such as baxrostat, gamizestrant, tozorakimab, and amplifying commercial investments. - Tozorakimab: Potential to be a $3-$5 billion asset with upside toward $10 billion depending on additional indications. - Tagrisso: Mid-teens demand growth expected, with stable U.S. - AstraZeneca expects total revenue to increase by mid- to high single-digit percentage in 2026.
What is AstraZeneca PLC share price analysis?
AstraZeneca PLC currently shows a below-average growth signal. The stock trades at a P/E of 28.1 with a market cap of $574,792. Investors should review the full earnings analysis for detailed insights.
Is AstraZeneca PLC planning capital expenditure?
- CapEx for Q1 2026 was $600 million, including previously announced multiyear investments.
Keep AstraZeneca PLC on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.